Abstract:The in silico investigation of a novel quinoline‐4‐carboxamide compound involves computational analyses targeting Gram‐positive bacteria. This includes 2D structure modeling, frontier molecular orbital (FMO) and electronic density (ED) simulations, physiochemical and pharmacokinetic profiling, protein‐ligand binding assessment, molecular docking, compound behavior simulations using Gromacs, and principal component analysis (PCA) with the Bio3D package, enhancing understanding of its antibacterial potential. Gram‐positive bacteria represent a significant threat due to their resistance to conventional antibiotics. This study employs computational methods to investigate fusidic acid (FA) derivatives (1–24) as potential antibiotics against Gram‐positive bacteria. Techniques such as density functional theory calculations, molecular docking, and molecular dynamics simulations were utilized to evaluate ligand interactions with target proteins Staphylococcus aureus (S. aureus) elongation factor G (fusA) (2XEX), fusidic acid resistance protein (fusB) (4ADN), and fusidic acid resistance protein (fusC) (2YB5), comparing them to established antibiotics (ceftobiprole, linezolid, vancomycin). Notably, ligand 16 demonstrated a remarkable binding affinity to the S. aureus elongation factor G protein (−8.7 kcal mol−1), closely aligning with both in vitro and in vivo results and outperforming fusidic acid and reference drugs. In silico methods (SwissADME, AdmetSAR, Molinspiration, Molsoft) were used to assess pharmacokinetics and drug‐likeness. Molecular dynamics (MD) simulations confirmed superior S. aureus elongation factor G stability for ligands fusidic acid 1, (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S,14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5‐cyclohexylidene‐ pentanoic acid (14), (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S, 14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5cyclohexylidenepentanoic acid (16), and (Z)‐2‐((3R,4S,8S,9R,10S,11R,13S,14S,16S)‐16‐acetoxy‐3,11‐dihydroxy‐4,8,10,14‐tetramethylhexadecahydro‐17H‐cyclopenta[a]phenanthren‐17‐ylidene)‐5‐cyclopentylidenepentanoic acid (17), with ligand 16 exhibiting exceptional stability across various temperatures, especially at human body temperature (310 K). Further molecular dynamics simulations of ligand 16 validated its robust stability and potential to disrupt S. aureus elongation factor G, supporting the docking results and showing strong consistency with in vitro and in vivo findings. Consequently, ligand 16 emerges as a promising candidate for further development as an anti‐Gram‐positive bacterial drug, pending validation through rigorous clinical trials.

Expanding the Chemical Diversity of Fasamycin Via Genome Mining and Biocatalysis

Extensive expansion of the chemical diversity of fusidane-type antibiotics using a stochastic combinational strategy

Generation of Fluorinated Amychelin Siderophores Against Pseudomonas Aeruginosa Infections by a Combination of Genome Mining and Mutasynthesis

Antimicrobial Furancarboxylic Acids from a Penicillium Sp.

Design and synthesis of fascaplysin derivatives as inhibitors of FtsZ with potent antibacterial activity and mechanistic study

Expanding the Bioactive Chemical Space of Anthrabenzoxocinones Through Engineering the Highly Promiscuous Biosynthetic Modification Steps.

Integrated Biofilm Modification and Transcriptional Analysis for Improving Fengycin Production in Bacillus amyloliquefaciens

Expanding the Chemical Diversity of Secondary Metabolites Produced by Two Marine-Derived Enterocin- and Wailupemycin-Producing Streptomyces Strains

New capoamycin-type antibiotics and polyene acids from marine Streptomyces fradiae PTZ0025

Old fusidane-type antibiotics for new challenges: Chemistry and biology

A Novel Chemical Biology and Computational Approach to Expedite the Discovery of New-Generation Polymyxins Against Life-Threatening Acinetobacter Baumannii

Hetiamacin E and F, New Amicoumacin Antibiotics from Bacillus subtilis PJS Using MS/MS-Based Molecular Networking

New starting points for antibiotics targeting P. aeruginosa FabF discovered by crystallographic fragment screening followed by hit expansion

Rational molecular design converting fascaplysin derivatives to potent broad-spectrum inhibitors against bacterial pathogens via targeting FtsZ

Expanding the substrate selectivity of the fimsbactin biosynthetic adenylation domain, FbsH

Metabolic Engineering of Bacillus Subtilis 168 for the Utilization of Arabinose to Synthesize the Antifungal Lipopeptide Fengycin

Discovery of Novel Bacterial FabH Inhibitors (Pyrazol-Benzimidazole Amide Derivatives): Design, Synthesis, Bioassay, Molecular Docking and Crystal Structure Determination

Simulating New Fusidic Acid Derivatives to Target Gram‐Positive Bacteria by Using Computational Methods

Three new sterigmatocystin analogues from marine-derived fungus Aspergillus versicolor MF359

Increasing Fengycin Production by Strengthening the Fatty Acid Synthesis Pathway and Optimizing Fermentation Conditions

Metabolomic Analysis of the Effect Glutamate on Fengycin-Overproducing Bacillus Subtilis ATCC 21332 with an Enhanced Fatty Acid Synthesis Pathway